John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Interest of serum antibodies in the diagnosis and monitoring of patients with chronic inflammatory bowel diseases: state of the art in 2016 Volume 23, issue 6, Juin 2016

Figures

  • Figure 1

Tables

Authors
1 CHU de Saint-Etienne, Laboratoire d’Immunologie, CIC 1408 INSERM, GIMAP EA3064,42023 Saint-Etienne, France
2 CHU de Saint-Etienne, Service de gastroentérologie, Université de Saint-Etienne, France
* Tirés à part

Inflammatory bowel diseases are relatively frequent autoimmune diseases among the population. Clinical examination, radiology, endoscopy and biology might be combined in order to diagnose these diseases and allow their monitoring. Biology is not only an help in the diagnosis of intestinal inflammatory diseases but also a help to distinguish Crohn's disease from ulcerative colitis or undifferentiated colitis. These markers are also interesting in preventing relapses, complications and monitoring of remission. Various types of markers will be described and developed in this review such as anti-glycan antibodies, anti-glycoprotein 2 and anti-macrophage colony-stimulating factor. Anti-glycan antibodies can be especially helpful for the diagnosis. When several markers are associated, they allow a prediction of inflammatory bowel disease complications. The anti-glycoprotein 2 antibodies, found in inflammatory biopsies are more present when gut ileum is affected or when there are complications such as pouchitis. Anti-macrophage colony-stimulating factor antibodies seem to be more useful for monitoring the activity and for the prediction of surgery complications than for the diagnosis of these diseases.